title: The toxicology and comorbidities of fatal cases involving quetiapine.
abstract: The use of quetiapine in Australia has increased rapidly in recent years. Anecdotal and post-marketing surveillance reports indicate an increase in quetiapine misuse in prisons as well as an increase in its availability on the black-market. This study examined a cohort of quetiapine-associated deaths occurring in Victoria, Australia, between 2001 and 2009, to determine the prevalence of deaths associated with this drug and to determine whether misuse represents a legitimate concern. Case details were extracted from the National Coronial Information System. There were 224 cases with an average age of 43 years of age (range 15-87 years). The cause of death was mostly drug toxicity (n = 114, 51 %), followed by natural disease (n = 60, 27 %), external injury (n = 31, 14 %) and unascertained causes (n = 19, 8 %). Depression and/or anxiety were common, observed in over a third of the cohort (80 cases, 36 %). About 20 % of cases did not mention a psychiatric diagnosis at all which raises the question of whether quetiapine had been prescribed correctly in these cases. Cardiovascular disease was the most commonly reported illness after mental disease. Quetiapine ranged in concentration from the limit of reporting (0.01 mg/L) to 110 mg/L. The median concentration of quetiapine was much lower in the natural disease deaths (0.25 mg/L) compared with drug caused deaths (0.7 mg/L). The most commonly co-administered drug was diazepam in 81 (36 %) cases. There were a small number of cases where quetiapine contributed to a death where it had not apparently been prescribed, including the death of a 15 year old boy and one of a 34 year old female. Overall, misuse of quetiapine did not appear to be a significant issue in this cohort; use of the drug only occasionally led to fatalities when used in excess or concomitantly with interacting drugs. However, considering that it is a recent social concern, it is possible that analysis of cases post 2009 would reveal more cases of quetiapine abuse. Close monitoring of quetiapine is therefore advised to prevent adverse outcomes, particularly in vulnerable populations such as substance abusers.
authors: Department of Forensic Medicine, Monash University, 57-83 Kavanagh Street, Southbank, VIC, 3006, Australia. jennifer.pilgrim@monash.edu
authors: Jennifer L
authors: JL
authors: Pilgrim
authors: Olaf H
authors: OH
authors: Drummer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000097:blood / Q000506:poisoning*; D002423:Cause of Death; D015897:Comorbidity; D003987:Dibenzothiazepines / Q000097:blood / Q000506:poisoning*; D004347:Drug Interactions; D062787:Drug Overdose / Q000097:blood / Q000401:mortality*; D005260:Female; D053593:Forensic Toxicology / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D019338:Polypharmacy; D063487:Prescription Drug Misuse / Q000401:mortality; D015995:Prevalence; D000069348:Quetiapine Fumarate; D012307:Risk Factors; D014739:Victoria / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate
references: Am Fam Physician. 2010 Mar 1;81(5):617-22
references: 20187598
references: Expert Opin Drug Saf. 2008 Nov;7(6):739-48
references: 18983220
references: Arch Gen Psychiatry. 2001 Dec;58(12):1161-7
references: 11735845
references: N Engl J Med. 2003 Oct 30;349(18):1738-49
references: 14585943
references: Nord J Psychiatry. 2008;62(5):342-5
references: 18752109
references: Br J Clin Pharmacol. 2011 Dec;72(6):871-8
references: 21679221
references: Am J Psychiatry. 2008 Jul;165(7):918
references: 18593794
references: J Clin Psychiatry. 2008 Jan;69(1):162-3
references: 18312052
references: Perspect Psychiatr Care. 2008 Jul;44(3):202-6
references: 18577126
references: J Clin Psychopharmacol. 2012 Oct;32(5):721-3
references: 22926614
references: Am J Med Genet. 2000 Spring;97(1):12-7
references: 10813800
references: Am J Psychiatry. 2001 Nov;158(11):1774-82
references: 11691681
references: Am J Health Syst Pharm. 2007 Apr 1;64(7):723-5
references: 17384357
references: Br J Psychiatry. 1997 Dec;171:502-8
references: 9519087
references: Curr Drug Saf. 2010 Jan;5(1):97-104
references: 20210726
references: Emerg Med Clin North Am. 2000 May;18(2):317-25, x
references: 10767887
references: Am J Psychiatry. 2005 Sep;162(9):1755-6
references: 16135642
references: Med Clin North Am. 1993 Jan;77(1):185-202
references: 8093494
references: J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):135-44
references: 7626956
references: Am J Health Syst Pharm. 2008 Apr 1;65(7):611-8
references: 18359967
references: Arch Gen Psychiatry. 2003 Dec;60(12):1187-92
references: 14662550
references: Aust N Z J Psychiatry. 2012 Mar;46(3):279-80
references: 22391290
references: J Forensic Sci. 2003 Jan;48(1):164-7
references: 12570220
references: Arch Gen Psychiatry. 1984 Jun;41(6):541-5
references: 6539584
references: Aust N Z J Psychiatry. 2000 Oct;34(5):880
references: 11037387
references: Psychiatry (Edgmont). 2010 Jan;7(1):13-6
references: 20386631